Structured evidence table for Saffron Sleep Quality Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Saffron Sleep Quality Randomized Trial | These limitations have catalyzed an increased global focus on nutraceuticals and phytomedicines possessing multimodal biological activities that transcend mere monoamine reuptake inhibition. | 3 | Li Xikun (2026) | Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders |
| Saffron Sleep Quality Randomized Trial | Unlike prior reviews that focus on individual herbs or broadly defined adaptogens, the present review integrates mechanistic, preclinical, and clinical evidence across these three agents to highlight their complementary rather than redundant actions. | 3 | Li Xikun (2026) | Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders |
| Saffron Sleep Quality Randomized Trial | Rhodiola rosea Ginkgo biloba Withania somnifera A comprehensive and structured literature search was conducted to identify preclinical, translational, and clinical evidence related to the antidepressant effects and underlying neurobiological mechanisms of,, and(Ashwagandha). | 3 | Li Xikun (2026) | Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders |
| Saffron Sleep Quality Randomized Trial | 1 2 3 Rhodiola rosea Ginkgo biloba Withania somnifera Depression constitutes one of the most incapacitating neuropsychiatric disorders globally (). | 3 | Li Xikun (2026) | Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders |
| Saffron Sleep Quality Randomized Trial | This narrative review critically evaluates clinical evidence on commonly used herbal preparations, with particular emphasis on herb-drug interactions, adverse effects, and issues related to product adulteration. | 3 | Căuș MN (2026) | Efficacy and Safety of Herbal Supplements with Anxiolytic, Antidepressant, and Sedative Action: A Review of Clinical Data and Toxicological Risks. |
| Saffron Sleep Quality Randomized Trial | However, clinically relevant risks were identified, including cytochrome P450-mediated drug interactions, excessive sedation, serotonin syndrome, and toxic effects associated with adulterated products, such as hepatotoxicity, cardiovascular events, and neurological disturbances. | 3 | Căuș MN (2026) | Efficacy and Safety of Herbal Supplements with Anxiolytic, Antidepressant, and Sedative Action: A Review of Clinical Data and Toxicological Risks. |
| Saffron Sleep Quality Randomized Trial | Increased awareness of herb-drug interactions and stricter quality control are essential to optimize therapeutic outcomes and minimize harm. | 3 | Căuș MN (2026) | Efficacy and Safety of Herbal Supplements with Anxiolytic, Antidepressant, and Sedative Action: A Review of Clinical Data and Toxicological Risks. |
| Saffron Sleep Quality Randomized Trial | Background/Objectives: Plant-based supplements are widely used for the management of anxiety, depression, and insomnia. | 3 | Căuș MN (2026) | Efficacy and Safety of Herbal Supplements with Anxiolytic, Antidepressant, and Sedative Action: A Review of Clinical Data and Toxicological Risks. |
Source documents